Is Compounded BPC-157 Safe and Legal?
Compounding Finder does not currently route BPC-157 quote requests. BPC-157 is not FDA-approved and is not on the FDA 503A bulk drug substances list. An FDA advisory committee voted in July 2026 to recommend adding it, but FDA has not acted, so US compounding pharmacies have no clear legal pathway to prepare it.
Read the BPC-157 background guide →The Short Answer
BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide studied mainly in animal models for tissue repair, tendon and ligament healing, and gut health. It is not FDA-approved for any use. Under Section 503A, a compounding pharmacy may only compound from a bulk ingredient that is part of an FDA-approved drug, has a USP or NF monograph, or is on FDA's 503A bulk drug substances list. BPC-157 meets none of these. In late 2023 FDA placed BPC-157 in Category 2, its list of bulk substances that may present significant safety risks. In April 2026 FDA took it off that list and now lists it among nominations that were withdrawn; that change did not add it to the 503A list. On July 23, 2026, FDA's Pharmacy Compounding Advisory Committee voted 8–6, with one abstention, to recommend adding BPC-157 to the list, although FDA's own reviewers had recommended against it. The vote is advisory. Adding a substance to the list takes FDA rulemaking, and as of October 2026 FDA has not proposed it. Until FDA acts, Compounding Finder does not send BPC-157 requests to pharmacies. We will update this page if that changes.
Who Is Eligible for Compounded BPC-157?
- Until FDA adds BPC-157 to the 503A bulk drug substances list, there is no clear legal pathway for a US compounding pharmacy to prepare it, even with a prescription.
- Providers have prescribed it most often for tendon, ligament, and muscle injuries; gut-healing protocols; and post-surgical tissue repair.
- Human clinical trial evidence is limited. If BPC-157 was suggested to you, ask your prescriber about FDA-approved treatments for the same condition.
Safety Considerations
- Most BPC-157 research is in animals. FDA has said it found little or no safety information for the proposed routes of use, and that BPC-157 may carry a risk of immune reactions by some routes and may raise problems with peptide-related impurities.
- Do not self-treat with BPC-157. Talk to a licensed prescriber about the condition you want treated and the FDA-approved options for it.
- Injectable peptides must be prepared under sterile conditions (USP <797>). Research-chemical vials are not made to that standard, so contamination and dosing errors are real risks.
- BPC-157 is prohibited by the World Anti-Doping Agency (WADA); competitive athletes should not use it.
Red Flags: What to Avoid
- Online sellers offering "BPC-157 for research use only" — these products have no pharmacy quality oversight and may be underdosed, contaminated, or counterfeit.
- Any seller that ships without a prescription.
- Overseas suppliers with no U.S. pharmacy license.
- Any seller or clinic that says BPC-157 is now FDA-approved or cleared for compounding. The July 2026 committee vote was advisory, and FDA has not acted on it.
Frequently Asked Questions
Can I request a BPC-157 quote through Compounding Finder?
Not at this time. BPC-157 is not on the FDA 503A bulk drug substances list, so Compounding Finder does not send BPC-157 requests to our pharmacy network. We will update this page if FDA adds it. We continue to publish legal and safety information on BPC-157 for patients researching it.
Is compounded BPC-157 legal in the United States?
BPC-157 is not FDA-approved and is not a DEA-scheduled substance. Under Section 503A, a compounding pharmacy may only use a bulk ingredient that is part of an FDA-approved drug, has a USP or NF monograph, or is on FDA's 503A bulk drug substances list. BPC-157 meets none of these, so there is no clear legal pathway for a 503A pharmacy to compound it. An FDA advisory committee voted in July 2026 to recommend adding it to the list, but that vote is advisory and FDA has not acted on it.
Is BPC-157 still in FDA's Category 2?
No. FDA placed BPC-157 in Category 2, its list of bulk substances that may present significant safety risks, in late 2023. In April 2026 FDA took it off that list and now lists it among nominations that were withdrawn. Leaving Category 2 did not make BPC-157 compoundable: it is not in Category 1, the substances FDA does not object to pharmacies using while it evaluates them, and it is not on the 503A list.
What did the FDA advisory committee decide in July 2026?
On July 23, 2026, FDA's Pharmacy Compounding Advisory Committee voted 8–6, with one abstention, to recommend adding BPC-157 to the 503A bulk drug substances list. At the same meeting it also recommended KPV, TB-500, MOTS-c, Epitalon, and Semax. FDA's own reviewers had recommended against all of them. The committee only advises FDA. Adding a substance to the list takes FDA rulemaking, and as of October 2026 FDA has not proposed it.
Why do some pharmacies still offer BPC-157?
Some pharmacies kept preparing BPC-157 after FDA's 2023 safety listing, and some treat the April 2026 change or the July 2026 vote as enough to go ahead. Neither added BPC-157 to the 503A list, so a pharmacy that compounds it is relying on its own reading of the rules. Compounding Finder will not route BPC-157 requests until FDA acts.
What about "research peptide" vendors selling BPC-157?
Non-pharmacy online vendors selling peptides labeled "for research use only" operate outside FDA and state pharmacy oversight. Products from these sources are frequently underdosed, contaminated, or mislabeled, and buyers have no recourse if harm occurs. These products are not legally intended for human use.
Keep Reading
Deep dive: Full article on BPC-157 from our blog →
Pharmacy basics: 503A vs 503B pharmacies — what's the difference? →
Vetting pharmacies: How to find a reputable compounding pharmacy →
Overview: Compounded BPC-157 — overview →
We Do Not Currently Route BPC-157 Quote Requests
Because of the FDA’s current stance on BPC-157, Compounding Finder is not sending BPC-157 quote requests to our pharmacy network at this time. If FDA guidance changes, we will revisit.
Read the BPC-157 background guide →